IPCALABPharmaceuticals
Ipca Laboratories Ltd — Profit & Loss Statement
₹1601.20
+1.02%
Ipca Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | -64.80 Cr | -19.88 Cr | 8.71 Cr | 0.74 Cr | — |
| Tax Rate For Calcs | 0.30 | 0.37 | 0.34 | 0.20 | — |
| Normalized EBITDA | 1.83K Cr | 1.39K Cr | 1.03K Cr | 1.37K Cr | — |
| Total Unusual Items | -213.32 Cr | -53.44 Cr | 25.63 Cr | 3.73 Cr | — |
| Total Unusual Items Excluding Goodwill | -213.32 Cr | -53.44 Cr | 25.63 Cr | 3.73 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 737.68 Cr | 547.35 Cr | 471.32 Cr | 884.08 Cr | — |
| Reconciled Depreciation | 397.82 Cr | 357.24 Cr | 261.56 Cr | 232.42 Cr | — |
| Reconciled Cost Of Revenue | 2.93K Cr | 2.73K Cr | 2.41K Cr | 2.11K Cr | — |
| EBITDA | 1.61K Cr | 1.34K Cr | 1.05K Cr | 1.38K Cr | — |
| EBIT | 1.22K Cr | 979.96 Cr | 790.38 Cr | 1.14K Cr | — |
| Net Interest Income | -52.72 Cr | -77.82 Cr | 31.16 Cr | 22.97 Cr | — |
| Interest Expense | 84.32 Cr | 137.29 Cr | 45.09 Cr | 7.24 Cr | — |
| Interest Income | 35.12 Cr | 62.93 Cr | 79.35 Cr | 34.17 Cr | — |
| Normalized Income | 886.20 Cr | 580.91 Cr | 454.40 Cr | 881.09 Cr | — |
| Net Income From Continuing And Discontinued Operation | 737.68 Cr | 547.35 Cr | 471.32 Cr | 884.08 Cr | — |
| Total Expenses | 7.50K Cr | 6.69K Cr | 5.50K Cr | 4.70K Cr | — |
| Rent Expense Supplemental | 17.75 Cr | 19.30 Cr | 16.41 Cr | 15.47 Cr | — |
| Depreciation And Amortization In Income Statement | 397.82 Cr | 357.24 Cr | 261.56 Cr | 232.42 Cr | — |
| Amortization | 19.97 Cr | 24.16 Cr | 25.37 Cr | 20.22 Cr | — |
| Depreciation Income Statement | 377.85 Cr | 333.08 Cr | 236.19 Cr | 212.20 Cr | — |
| Research And Development | 80.54 Cr | 71.83 Cr | 46.13 Cr | 41.79 Cr | — |
| Selling General And Administration | 999.39 Cr | 826.03 Cr | 632.36 Cr | 443.33 Cr | — |
| Selling And Marketing Expense | 875.64 Cr | 708.63 Cr | 556.17 Cr | 369.68 Cr | — |
| General And Administrative Expense | 123.75 Cr | 117.40 Cr | 76.19 Cr | 73.65 Cr | — |
| Rent And Landing Fees | 17.75 Cr | 19.30 Cr | 16.41 Cr | 15.47 Cr | — |
| Gross Profit | 5.92K Cr | 4.90K Cr | 3.80K Cr | 3.66K Cr | — |
| Cost Of Revenue | 2.93K Cr | 2.73K Cr | 2.41K Cr | 2.11K Cr | — |
| Total Revenue | 8.85K Cr | 7.62K Cr | 6.21K Cr | 5.77K Cr | — |
| Operating Revenue | 8.85K Cr | 7.62K Cr | 6.21K Cr | 5.77K Cr | — |
| Diluted Average Shares | 25.37 Cr | 25.37 Cr | 25.37 Cr | 25.37 Cr | — |
| Basic Average Shares | 25.37 Cr | 25.37 Cr | 25.37 Cr | 25.37 Cr | — |
| Diluted EPS | 29.08 | 21.57 | 18.58 | 34.85 | — |
| Basic EPS | 29.08 | 21.57 | 18.58 | 34.85 | — |
| Diluted NI Availto Com Stockholders | 737.68 Cr | 547.35 Cr | 471.32 Cr | 884.08 Cr | — |
| Net Income Common Stockholders | 737.68 Cr | 547.35 Cr | 471.32 Cr | 884.08 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 737.68 Cr | 547.35 Cr | 471.32 Cr | 884.08 Cr | — |
| Minority Interests | -47.56 Cr | 24.43 Cr | -7.67 Cr | -5.71 Cr | — |
| Net Income Including Noncontrolling Interests | 785.24 Cr | 522.92 Cr | 478.99 Cr | 889.79 Cr | — |
| Net Income Continuous Operations | 785.24 Cr | 522.92 Cr | 478.99 Cr | 889.79 Cr | — |
| Tax Provision | 343.61 Cr | 313.46 Cr | 253.36 Cr | 224.77 Cr | — |
| Pretax Income | 1.13K Cr | 842.67 Cr | 745.29 Cr | 1.14K Cr | — |
| Other Non Operating Income Expenses | 8.30 Cr | 6.51 Cr | 15.25 Cr | 15.57 Cr | — |
| Special Income Charges | -259.94 Cr | -108.15 Cr | 10.66 Cr | -12.19 Cr | — |
| Other Special Charges | -0.74 Cr | 57.35 Cr | -13.21 Cr | 11.39 Cr | — |
| Write Off | 147.54 Cr | 11.76 Cr | 2.55 Cr | 0.80 Cr | — |
| Impairment Of Capital Assets | 113.14 Cr | 0.00 | — | 0.00 | 15.84 Cr |
| Restructuring And Mergern Acquisition | 0.00 | 39.04 Cr | 0.00 | — | — |
| Net Non Operating Interest Income Expense | -52.72 Cr | -77.82 Cr | 31.16 Cr | 22.97 Cr | — |
| Total Other Finance Cost | 3.52 Cr | 3.46 Cr | 3.10 Cr | 3.96 Cr | — |
| Interest Expense Non Operating | 84.32 Cr | 137.29 Cr | 45.09 Cr | 7.24 Cr | — |
| Interest Income Non Operating | 35.12 Cr | 62.93 Cr | 79.35 Cr | 34.17 Cr | — |
| Operating Income | 1.36K Cr | 934.47 Cr | 704.76 Cr | 1.06K Cr | — |
| Operating Expense | 4.57K Cr | 3.96K Cr | 3.09K Cr | 2.60K Cr | — |
| Other Operating Expenses | 1.05K Cr | 947.68 Cr | 774.93 Cr | 651.41 Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Ipca Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.